Logos Global Management LP
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Logos Global Management LP reported 52 stock positions worth $1.0 billion. Its top holding was Revolution Medicines (RVMD) at 8.1% of the portfolio, followed by Ideaya Biosciences (IDYA, 6.0%) and Akero Therapeutics (AKRO, 5.6%). Compared with Q2 2025, it opened 21 new positions, sold out of 13, added to 13 and reduced 13. The biggest buy was a new position in Abivax SA-ADR (ABVX) and the biggest sale Jazz Pharmaceuticals (JAZZ, shares −56%).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $1.0B (Q3 2025)
- SEC Filing
- 0001172661-25-004983 ↗ filed Nov 14, 2025
Holdings Value
Holdings 52 stocks · $1.0B
| RVMD Revolution Medicines Inc. | 8.07% | 1,750,000 | $81.7M | Add +2.9% |
| IDYA Ideaya Biosciences Inc. | 6.05% | 2,250,000 | $61.2M | Reduce -32.7% |
| AKRO Akero Therapeutics Inc. | 5.63% | 1,200,000 | $57.0M | No change |
| ARVN Arvinas Inc. | 4.69% | 5,575,000 | $47.5M | Add +68.9% |
| OCUL Ocular Therapeutix Inc. | 3.75% | 3,250,000 | $38.0M | Add +47.7% |
| CDTX Cidara Therapeutics Inc. | 3.55% | 375,000 | $35.9M | Add +97.4% |
| VSTM Verastem Inc. | 3.53% | 4,050,000 | $35.8M | Add +305.0% |
| ABVX Abivax SA-ADR | 3.48% | 415,000 | $35.2M | New |
| ERAS Erasca Inc. | 3.26% | 15,150,000 | $33.0M | Add +1.0% |
| MAZE Maze Therapeutics Inc. | 3.14% | 1,227,300 | $31.8M | Add +100.6% |
| OLMA Olema Pharmaceuticals Inc. | 3.10% | 3,208,875 | $31.4M | No change |
| IMCR Immunocore Holdings PLC-ADR | 3.05% | 850,000 | $30.9M | Add +47.8% |
| DYN Dyne Therapeutics Inc. | 3.00% | 2,400,000 | $30.4M | Add +26.3% |
| IRON Disc Medicine Inc. | 2.94% | 450,000 | $29.7M | Reduce -35.7% |
| DSGN Design Therapeutics Inc. | 2.72% | 3,655,000 | $27.5M | Reduce -13.3% |
| JAZZ Jazz Pharmaceuticals PLC | 2.60% | 200,000 | $26.4M | Reduce -55.6% |
| RNAM Avidity Biosciences Inc. | 2.58% | 600,000 | $26.1M | Reduce -36.8% |
| GPCR Structure Therapeutics Inc. | 2.35% | 850,000 | $23.8M | No change |
| JANX Janux Therapeutics Inc. | 2.26% | 935,000 | $22.9M | Reduce -6.5% |
| PCVX Vaxcyte Inc. | 2.22% | 625,000 | $22.5M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 2.00% | 200,000 | $20.2M | Add +53.9% |
| TRVI Trevi Therapeutics Inc. | 1.99% | 2,200,000 | $20.1M | Add +158.8% |
| PTGX Protagonist Therapeutics Inc. | 1.97% | 300,000 | $19.9M | New |
| AMLX Amylyx Pharmaceuticals Inc. | 1.95% | 1,450,000 | $19.7M | New |
| LBRX LB Pharmaceuticals Inc. | 1.76% | 1,130,000 | $17.8M | New |
| QURE Uniqure NV | 1.73% | 300,000 | $17.5M | New |
| KYMR Kymera Therapeutics Inc. | 1.40% | 250,000 | $14.2M | New |
| BIIB Biogen Inc. | 1.38% | 100,000 | $14.0M | Reduce -50.0% |
| ACLX Arcellx Inc. | 1.34% | 165,000 | $13.5M | New |
| KROS Keros Therapeutics Inc. | 1.33% | 850,000 | $13.4M | Reduce -57.5% |
| CNTA Centessa Pharmaceuticals Ltd. | 1.26% | 525,000 | $12.7M | New |
| TNGX Tango Therapeutics Inc. | 0.79% | 950,000 | $8.0M | New |
| DNTH Dianthus Therapeutics Inc. | 0.78% | 200,000 | $7.9M | New |
| COGT Cogent Biosciences Inc. | 0.71% | 500,000 | $7.2M | New |
| CMPX Compass Therapeutics Inc. | 0.71% | 2,050,000 | $7.2M | New |
| CBIO Crescent Biopharma Inc. | 0.70% | 600,000 | $7.1M | Add +8.4% |
| ELVN Enliven Therapeutics Inc. | 0.69% | 340,000 | $7.0M | Reduce -2.9% |
| IMRX Immuneering Corp. Class A | 0.66% | 950,000 | $6.7M | New |
| PRAX Praxis Precision Medicines I | 0.65% | 125,000 | $6.6M | Reduce -44.4% |
| SRRK Scholar Rock Holding Corp. | 0.64% | 175,000 | $6.5M | New |
| JBIO Jade Biosciences Inc. | 0.53% | 625,000 | $5.4M | No change |
| EPRX Eupraxia Pharmaceuticals Inc. | 0.52% | 900,000 | $5.3M | New |
| IMVT Immunovant Inc. | 0.44% | 275,000 | $4.4M | No change |
| PHVS Pharvaris NV | 0.37% | 150,000 | $3.7M | New |
| ATXS Astria Therapeutics Inc. | 0.36% | 500,000 | $3.6M | Reduce -28.6% |
| PEPG Pepgen Inc. | 0.34% | 750,000 | $3.5M | New |
| ACRS Aclaris Therapeutics Inc. | 0.28% | 1,500,000 | $2.9M | Reduce -18.9% |
| UNCY Unicycive Therapeutics Inc. | 0.20% | 473,563 | $2.1M | Add +0.0% |
| ESPR Esperion Therapeutics Inc. | 0.20% | 750,000 | $2.0M | New |
| SEPN Septerna Inc. | 0.16% | 83,548 | $1.6M | Reduce -23.5% |
| MREO Mereo Biopharma Group PL-ADR | 0.10% | 500,000 | $1.0M | New |
| GUTS Fractyl Health Inc. | 0.08% | 500,000 | $795K | New |
Options reported separately and not counted above: RVMD calls ($46.7M), APLS calls ($22.6M), IDYA calls ($12.2M), JANX calls ($12.2M), LRMR calls ($8.1M), ALEC calls ($1.5M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $13K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 66,666 | $13K | No change |
Total filed on the 13F, all lines: $1.0B.
Portfolio Sells Q2 2025 → Q3 2025
| JAZZ Jazz Pharmaceuticals PLC | Reduce -55.6% | 2.60% | −3.78 |
| IDYA Ideaya Biosciences Inc. | Reduce -32.7% | 6.05% | −3.34 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −3.26 |
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −2.52 |
| KROS Keros Therapeutics Inc. | Reduce -57.5% | 1.33% | −2.24 |
| MDGL Madrigal Pharmaceuticals Inc. | Sold out | 0.00% | −2.02 |
| IRON Disc Medicine Inc. | Reduce -35.7% | 2.94% | −2.01 |
| BIIB Biogen Inc. | Reduce -50.0% | 1.38% | −1.97 |
| KRYS Krystal Biotech Inc. | Sold out | 0.00% | −1.84 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −1.63 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −1.32 |
| XNCR Xencor Inc. | Sold out | 0.00% | −1.31 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −1.26 |
| LEGN Legend Biotech Corp.-ADR | Sold out | 0.00% | −1.19 |
| RNAM Avidity Biosciences Inc. | Reduce -36.8% | 2.58% | −1.02 |
| JANX Janux Therapeutics Inc. | Reduce -6.5% | 2.26% | −0.83 |
| ANNX Annexon Inc. | Sold out | 0.00% | −0.77 |
| MTSR Metsera Inc. | Sold out | 0.00% | −0.76 |
| PRAX Praxis Precision Medicines I | Reduce -44.4% | 0.65% | −0.61 |
| BCAX Bicara Therapeutics Inc. | Sold out | 0.00% | −0.50 |
| RAPP Rapport Therapeutics Inc. | Sold out | 0.00% | −0.32 |
| ELVN Enliven Therapeutics Inc. | Reduce -2.9% | 0.69% | −0.25 |
| ATXS Astria Therapeutics Inc. | Reduce -28.6% | 0.36% | −0.14 |
| ACRS Aclaris Therapeutics Inc. | Reduce -18.9% | 0.28% | −0.07 |
| SEPN Septerna Inc. | Reduce -23.5% | 0.16% | +0.00 |
| DSGN Design Therapeutics Inc. | Reduce -13.3% | 2.72% | +0.82 |
Portfolio Buys Q2 2025 → Q3 2025
| ABVX Abivax SA-ADR | New | 3.48% | +3.48 |
| VSTM Verastem Inc. | Add +305.0% | 3.53% | +2.98 |
| CDTX Cidara Therapeutics Inc. | Add +97.4% | 3.55% | +2.31 |
| PCVX Vaxcyte Inc. | New | 2.22% | +2.22 |
| MAZE Maze Therapeutics Inc. | Add +100.6% | 3.14% | +2.14 |
| PTGX Protagonist Therapeutics Inc. | New | 1.97% | +1.97 |
| AMLX Amylyx Pharmaceuticals Inc. | New | 1.95% | +1.95 |
| LBRX LB Pharmaceuticals Inc. | New | 1.76% | +1.76 |
| QURE Uniqure NV | New | 1.73% | +1.73 |
| ARVN Arvinas Inc. | Add +68.9% | 4.69% | +1.45 |
| KYMR Kymera Therapeutics Inc. | New | 1.40% | +1.40 |
| TRVI Trevi Therapeutics Inc. | Add +158.8% | 1.99% | +1.37 |
| ACLX Arcellx Inc. | New | 1.34% | +1.34 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 1.26% | +1.26 |
| OCUL Ocular Therapeutix Inc. | Add +47.7% | 3.75% | +1.03 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +53.9% | 2.00% | +0.90 |
| TNGX Tango Therapeutics Inc. | New | 0.79% | +0.79 |
| DNTH Dianthus Therapeutics Inc. | New | 0.78% | +0.78 |
| ERAS Erasca Inc. | Add +1.0% | 3.26% | +0.72 |
| COGT Cogent Biosciences Inc. | New | 0.71% | +0.71 |
| CMPX Compass Therapeutics Inc. | New | 0.71% | +0.71 |
| IMRX Immuneering Corp. Class A | New | 0.66% | +0.66 |
| SRRK Scholar Rock Holding Corp. | New | 0.64% | +0.64 |
| IMCR Immunocore Holdings PLC-ADR | Add +47.8% | 3.05% | +0.64 |
| DYN Dyne Therapeutics Inc. | Add +26.3% | 3.00% | +0.58 |
| EPRX Eupraxia Pharmaceuticals Inc. | New | 0.52% | +0.52 |
| PHVS Pharvaris NV | New | 0.37% | +0.37 |
| PEPG Pepgen Inc. | New | 0.34% | +0.34 |
| ESPR Esperion Therapeutics Inc. | New | 0.20% | +0.20 |
| MREO Mereo Biopharma Group PL-ADR | New | 0.10% | +0.10 |
| GUTS Fractyl Health Inc. | New | 0.08% | +0.08 |
| UNCY Unicycive Therapeutics Inc. | Add +0.0% | 0.20% | −0.10 |
| RVMD Revolution Medicines Inc. | Add +2.9% | 8.07% | −0.28 |
| CBIO Crescent Biopharma Inc. | Add +8.4% | 0.70% | −0.49 |
Options Activity Q2 2025 → Q3 2025
| XBI SS SPDR S&P Biotech ETF | call | Sold out | 1,000,000 | $82.9Mbefore exit |
| RVMD Revolution Medicines Inc. | call | New | 1,000,000 | $46.7M |
| TEVA Teva Pharmaceutical-SP ADR | call | Sold out | 1,500,000 | $25.1Mbefore exit |
| IDYA Ideaya Biosciences Inc. | call | New | 450,000 | $12.2M |
| ARVN Arvinas Inc. | call | Sold out | 1,500,000 | $11.0Mbefore exit |
| ALEC Alector Inc. | call | New | 500,000 | $1.5M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |